Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

Bibliographic Details
Published in:	The Journal of Headache and Pain
Main Authors:	Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Florindo d’Onofrio, Maria Albanese, Ilaria Cetta, Paola Di Fiore, Maurizio Zucco, Massimo Filippi, Francesco Bono, Claudia Altamura, Stefania Proietti, Stefano Bonassi, Fabrizio Vernieri, and for the FRIEND-Study Group
Format:	Article
Language:	English
Published:	BMC 2022-04-01
Online Access:	https://doi.org/10.1186/s10194-022-01422-y

Similar Items

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
by: Piero Barbanti, et al.
Published: (2022-04-01)

Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
by: Piero Barbanti, et al.
Published: (2022-06-01)

Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
by: Piero Barbanti, et al.
Published: (2023-03-01)

Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
by: Piero Barbanti, et al.
Published: (2024-03-01)

Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
by: Piero Barbanti, et al.
Published: (2024-08-01)

Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE—The First Italian Multicenter, Prospective, Real-Life Study
by: Piero Barbanti, et al.
Published: (2024-06-01)

Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine
by: Root S, et al.
Published: (2023-02-01)

Very-low-calorie ketogenic diet vs hypocaloric balanced diet in the prevention of high-frequency episodic migraine: the EMIKETO randomized, controlled trial
by: Massimiliano Caprio, et al.
Published: (2023-10-01)

Fremanezumab in the treatment of migraines: evidence to date
by: Robblee J, et al.
Published: (2019-08-01)

Fremanezumab for Episodic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials
by: Saigoh K, et al.
Published: (2023-05-01)

An Evidence-Based Review of Fremanezumab for the Treatment of Migraine
by: Ivan Urits, et al.
Published: (2020-03-01)

Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence
by: Bianca Orlando, et al.
Published: (2024-09-01)

Evaluating the wearing-off effects of fremanezumab in high-frequency episodic migraine and chronic migraine: A real-world observational study in Japan
by: Shiho Suzuki, et al.
Published: (2023-10-01)

Efficacy of fremanezumab in patients with chronic migraine and concomitant depression
by: A.Y. Timokhovich, et al.
Published: (2024-10-01)

Treatment of migraine with fremanezumab and sleep: A preliminary case series
by: Agustin Melo-Carrillo, et al.
Published: (2025-08-01)

Reversion of chronic to episodic migraine in working age and botulinum toxin‐resistant patients treated with fremanezumab: A real‐life study
by: Juan Tudela‐Tomas, et al.
Published: (2024-07-01)

Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study
by: Fabrizio Vernieri, et al.
Published: (2021-12-01)

Safety and efficacy of fremanezumab in real clinical practice in patients with chronic migraine
by: G. N. Belskaya, et al.
Published: (2024-02-01)

Fremanezumab for refractory migraine in patients with hereditary transthyretin amyloidosis: A case series
by: Joana Fernandes, et al.
Published: (2025-03-01)

Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study
by: Seiya Ohtani, et al.
Published: (2023-11-01)

Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan
by: Shiho Suzuki, et al.
Published: (2023-07-01)

GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures
by: Piero Barbanti, et al.
Published: (2025-05-01)

Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study
by: Messoud Ashina, et al.
Published: (2021-07-01)

Physical activity as a predictor of fremanezumab response in chronic migraine – the Phy-Fre-Mig study
by: Álvaro Sierra-Mencía, et al.
Published: (2025-02-01)

Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients with Migraine: Three Cases
by: Kenta Kashiwagi, et al.
Published: (2023-02-01)

Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials
by: Saigoh K, et al.
Published: (2023-04-01)

Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials
by: Bixi Gao, et al.
Published: (2020-05-01)

Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine—A Real-Life Study
by: Magdalena Nowaczewska, et al.
Published: (2022-05-01)

Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE)
by: Piero Barbanti, et al.
Published: (2025-10-01)

Machine learning approach to predict medication overuse in migraine patients
by: Patrizia Ferroni, et al.
Published: (2020-01-01)

A real-world study of the efficacy and tolerability of fremanezumab in migraine patients with a median follow-up of 14 months
by: Shiho Suzuki, et al.
Published: (2025-06-01)

Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response
by: Dawn C. Buse, et al.
Published: (2024-03-01)

The Role of the Combination Paracetamol/Caffeine in Treatment of Acute Migraine Pain: A Narrative Review
by: Piero Barbanti, et al.
Published: (2024-03-01)

Real-world efficacy and tolerability of fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, observational study
by: Christopher Kjaer Cullum, et al.
Published: (2023-08-01)

Correction: The Role of the Combination Paracetamol/Caffeine in Treatment of Acute Migraine Pain: A Narrative Review
by: Piero Barbanti, et al.
Published: (2024-05-01)

Comparative Clinical Efficacy Study between Erenumab and Fremanezumab
by: Raquel Fresquet, et al.
Published: (2022-11-01)

Tolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational study
by: Faisal Mohammad Amin, et al.
Published: (2025-07-01)

A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy
by: Sharon Wolters, et al.
Published: (2024-06-01)

Episodic migraine and transformed migraine: a comparative study
by: José Carlos Busto Galego
Published: (2001-09-01)

Episodic Mydriasis as Migraine Equivalent
by: J Gordon Millichap
Published: (1991-10-01)